Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM
 |
| Bispecific Antibody Therapies in Multiple Myeloma: Revolutionizing Treatment Panelists discuss how bispecific antibody therapies are revolutionizing multiple myeloma treatment by providing highly effective, accessible options for heavily pretreated patients while addressing key implementation challenges including patient selection, sequencing strategies, safety management protocols, and the transition from academic centers to community-based care delivery. Watch Now |
|
Featured Video |
 |
| Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients. Watch Now |